TOP CATEGORY: Chemicals & Materials | Life Sciences | Banking & Finance | ICT Media

Global Influenza (Flu) Antiviral Drugs Market Research Report 2023

Global Influenza (Flu) Antiviral Drugs Market Research Report 2023

  • Category:Life Sciences
  • Published on : 02 May 2023
  • Pages :95
  • Formats:
  • Report Code:SMR-7667682

Market Analysis and Insights: Global Influenza Flu Antiviral Drugs Market

The global Influenza Flu Antiviral Drugs market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027.

With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Influenza Flu Antiviral Drugs market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Influenza Flu Antiviral Drugs market in terms of revenue.

On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Influenza Flu Antiviral Drugs market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Influenza Flu Antiviral Drugs market.

Global Influenza Flu Antiviral Drugs Scope and Market Size

Influenza (Flu) Antiviral Drugs market is segmented by players, region (country), by Type and by Application. Players, stakeholders, and other participants in the global Influenza (Flu) Antiviral Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application for the period 2018-2029.
Segment by Type
Penetration and Dehulling Inhibitors
DNA Polymerase Inhibitors
Reverse Transcriptase Inhibitors
Protein Inhibitors
Neuraminidase Inhibitors
Broad-spectrum Antiviral Drugs
Segment by Application
Hospital
Clinic
Household
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
By Company
Pfizer
Roche
Sanofi
Johnson & Johnson
Merck & Co. (MSD)
Novartis
AbbVie
Gilead Sciences
GlaxoSmithKline (GSK)
Amgen
AstraZeneca
Bristol-Myers Squibb
Eli Lilly
Teva
Bayer
Novo Nordisk
Allergan
Takeda
Boehringer Ingelheim

The information for each competitor/Company Profile includes:

  • Company Overview
  • Business Strategy
  • Key Product Offerings
  • Financial Performance
  • Key Performance Indicators
  • Risk Analysis
  • Recent Development
  • Regional Presence
  • SWOT Analysis 

The content of the study subjects includes a total of 15 chapters:

Chapter 1, describes Influenza Flu Antiviral Drugs product scope, market overview, market opportunities, market driving force, and market risks.

Chapter 2, profiles the top manufacturers of Influenza Flu Antiviral Drugs, with price, sales, revenue, and global market share of Influenza Flu Antiviral Drugs from 2019 to 2022.

Chapter 3, the Influenza Flu Antiviral Drugs competitive situation, sales, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.

Chapter 4, the Influenza Flu Antiviral Drugs breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2017 to 2028.

Chapters 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, and application, from 2017 to 2028.

Chapters 7, 8, 9, 10, and 11, to break the sales data at the country level, with sales, revenue, and market share for key countries in the world, from 2017 to 2022. and the Influenza Flu Antiviral Drugs market forecast, by regions, type, and application, with sales and revenue, from 2023 to 2028.

Chapter 12, the key raw materials and key suppliers, and industry chain of Influenza Flu Antiviral Drugs.

Chapter 13, 14, and 15, to describe Influenza Flu Antiviral Drugs sales channel, distributors, customers, research findings and conclusion, appendix and data source.

Key Indicators Analysed:

  • Market Players & Competitor Analysis: The report covers the key players of the industry including Company Profile, Product Specifications, Production Capacity/Sales, Revenue, Price and Gross Margin 2016-2027 & Sales with a thorough analysis of the market?s competitive landscape and detailed information on vendors and comprehensive details of factors that will challenge the growth of major market vendors.
  • Global and Regional Market Analysis: The report includes Global & Regional market status and outlook 2016-2027. Further the report provides break down details about each region & countries covered in the report. Identifying its sales, sales volume & revenue forecast. With detailed analysis by types and applications.
  • Market Trends: Market key trends which include Increased Competition and Continuous Innovations.
  • Opportunities and Drivers: Identifying the Growing Demands and New Technology
  • Porters Five Force Analysis: The report provides with the state of competition in industry depending on five basic forces: threat of new entrants, bargaining power of suppliers, bargaining power of buyers, threat of substitute products or services, and existing industry rivalry.

Reasons to Purchase this Report:

  • Estimates 2022-2027 2021-2025 Influenza Flu Antiviral Drugs Report on, Status and Forecast, by Players, Types and Applications market development trends with the recent trends and SWOT analysis
  • Market dynamics scenario, along with growth opportunities of the market in the years to come
  • Market segmentation analysis including qualitative and quantitative research incorporating the impact of economic and policy aspects
  • Regional and country level analysis integrating the demand and supply forces that are influencing the growth of the market.
  • Market value (USD Million) and volume (Units Million) data for each segment and sub-segment
  • Competitive landscape involving the market share of major players, along with the new projects and strategies adopted by players in the past five years
  • Comprehensive company profiles covering the product offerings, key financial information, recent developments, SWOT analysis, and strategies employed by the major market players
  • 1-year analyst support, along with the data support in excel format.

Research Methodology:

The research methodology used to estimate and forecast this market begins by capturing the revenues of the key players and their shares in the market. Various secondary sources such as press releases, annual reports, non-profit organizations, industry associations, governmental agencies and customs data, have been used to identify and collect information useful for this extensive commercial study of the market. Calculations based on this led to the overall market size. After arriving at the overall market size, the total market has been split into several segments and subsegments, which have then been verified through primary research by conducting extensive interviews with industry experts such as CEOs, VPs, directors, and executives. The data triangulation and market breakdown procedures have been employed to complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments.

TABLE OF CONTENTS

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Influenza (Flu) Antiviral Drugs Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Penetration and Dehulling Inhibitors
1.2.3 DNA Polymerase Inhibitors
1.2.4 Reverse Transcriptase Inhibitors
1.2.5 Protein Inhibitors
1.2.6 Neuraminidase Inhibitors
1.2.7 Broad-spectrum Antiviral Drugs
1.3 Market by Application
1.3.1 Global Influenza (Flu) Antiviral Drugs Market Share by Application: 2018 VS 2022 VS 2029
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Household
1.3.5 Others
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Influenza (Flu) Antiviral Drugs Market Perspective (2018-2029)
2.2 Influenza (Flu) Antiviral Drugs Growth Trends by Region
2.2.1 Influenza (Flu) Antiviral Drugs Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Influenza (Flu) Antiviral Drugs Historic Market Size by Region (2018-2023)
2.2.3 Influenza (Flu) Antiviral Drugs Forecasted Market Size by Region (2024-2029)
2.3 Influenza (Flu) Antiviral Drugs Market Dynamics
2.3.1 Influenza (Flu) Antiviral Drugs Industry Trends
2.3.2 Influenza (Flu) Antiviral Drugs Market Drivers
2.3.3 Influenza (Flu) Antiviral Drugs Market Challenges
2.3.4 Influenza (Flu) Antiviral Drugs Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Influenza (Flu) Antiviral Drugs Players by Revenue
3.1.1 Global Top Influenza (Flu) Antiviral Drugs Players by Revenue (2018-2023)
3.1.2 Global Influenza (Flu) Antiviral Drugs Revenue Market Share by Players (2018-2023)
3.2 Global Influenza (Flu) Antiviral Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Influenza (Flu) Antiviral Drugs Revenue
3.4 Global Influenza (Flu) Antiviral Drugs Market Concentration Ratio
3.4.1 Global Influenza (Flu) Antiviral Drugs Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Influenza (Flu) Antiviral Drugs Revenue in 2022
3.5 Influenza (Flu) Antiviral Drugs Key Players Head office and Area Served
3.6 Key Players Influenza (Flu) Antiviral Drugs Product Solution and Service
3.7 Date of Enter into Influenza (Flu) Antiviral Drugs Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Influenza (Flu) Antiviral Drugs Breakdown Data by Type
4.1 Global Influenza (Flu) Antiviral Drugs Historic Market Size by Type (2018-2023)
4.2 Global Influenza (Flu) Antiviral Drugs Forecasted Market Size by Type (2024-2029)
5 Influenza (Flu) Antiviral Drugs Breakdown Data by Application
5.1 Global Influenza (Flu) Antiviral Drugs Historic Market Size by Application (2018-2023)
5.2 Global Influenza (Flu) Antiviral Drugs Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America Influenza (Flu) Antiviral Drugs Market Size (2018-2029)
6.2 North America Influenza (Flu) Antiviral Drugs Market Size by Country (2018-2023)
6.3 North America Influenza (Flu) Antiviral Drugs Market Size by Country (2024-2029)
6.4 United States
6.5 Canada
7 Europe
7.1 Europe Influenza (Flu) Antiviral Drugs Market Size (2018-2029)
7.2 Europe Influenza (Flu) Antiviral Drugs Market Size by Country (2018-2023)
7.3 Europe Influenza (Flu) Antiviral Drugs Market Size by Country (2024-2029)
7.4 Germany
7.5 France
7.6 U.K.
7.7 Italy
7.8 Russia
7.9 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Influenza (Flu) Antiviral Drugs Market Size (2018-2029)
8.2 Asia-Pacific Influenza (Flu) Antiviral Drugs Market Size by Country (2018-2023)
8.3 Asia-Pacific Influenza (Flu) Antiviral Drugs Market Size by Country (2024-2029)
8.4 China
8.5 Japan
8.6 South Korea
8.7 Southeast Asia
8.8 India
8.9 Australia
9 Latin America
9.1 Latin America Influenza (Flu) Antiviral Drugs Market Size (2018-2029)
9.2 Latin America Influenza (Flu) Antiviral Drugs Market Size by Country (2018-2023)
9.3 Latin America Influenza (Flu) Antiviral Drugs Market Size by Country (2024-2029)
9.4 Mexico
9.5 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Influenza (Flu) Antiviral Drugs Market Size (2018-2029)
10.2 Middle East & Africa Influenza (Flu) Antiviral Drugs Market Size by Country (2018-2023)
10.3 Middle East & Africa Influenza (Flu) Antiviral Drugs Market Size by Country (2024-2029)
10.4 Turkey
10.5 Saudi Arabia
10.6 UAE
11 Key Players Profiles
11.1 Pfizer
11.1.1 Pfizer Company Detail
11.1.2 Pfizer Business Overview
11.1.3 Pfizer Influenza (Flu) Antiviral Drugs Introduction
11.1.4 Pfizer Revenue in Influenza (Flu) Antiviral Drugs Business (2018-2023)
11.1.5 Pfizer Recent Development
11.2 Roche
11.2.1 Roche Company Detail
11.2.2 Roche Business Overview
11.2.3 Roche Influenza (Flu) Antiviral Drugs Introduction
11.2.4 Roche Revenue in Influenza (Flu) Antiviral Drugs Business (2018-2023)
11.2.5 Roche Recent Development
11.3 Sanofi
11.3.1 Sanofi Company Detail
11.3.2 Sanofi Business Overview
11.3.3 Sanofi Influenza (Flu) Antiviral Drugs Introduction
11.3.4 Sanofi Revenue in Influenza (Flu) Antiviral Drugs Business (2018-2023)
11.3.5 Sanofi Recent Development
11.4 Johnson & Johnson
11.4.1 Johnson & Johnson Company Detail
11.4.2 Johnson & Johnson Business Overview
11.4.3 Johnson & Johnson Influenza (Flu) Antiviral Drugs Introduction
11.4.4 Johnson & Johnson Revenue in Influenza (Flu) Antiviral Drugs Business (2018-2023)
11.4.5 Johnson & Johnson Recent Development
11.5 Merck & Co. (MSD)
11.5.1 Merck & Co. (MSD) Company Detail
11.5.2 Merck & Co. (MSD) Business Overview
11.5.3 Merck & Co. (MSD) Influenza (Flu) Antiviral Drugs Introduction
11.5.4 Merck & Co. (MSD) Revenue in Influenza (Flu) Antiviral Drugs Business (2018-2023)
11.5.5 Merck & Co. (MSD) Recent Development
11.6 Novartis
11.6.1 Novartis Company Detail
11.6.2 Novartis Business Overview
11.6.3 Novartis Influenza (Flu) Antiviral Drugs Introduction
11.6.4 Novartis Revenue in Influenza (Flu) Antiviral Drugs Business (2018-2023)
11.6.5 Novartis Recent Development
11.7 AbbVie
11.7.1 AbbVie Company Detail
11.7.2 AbbVie Business Overview
11.7.3 AbbVie Influenza (Flu) Antiviral Drugs Introduction
11.7.4 AbbVie Revenue in Influenza (Flu) Antiviral Drugs Business (2018-2023)
11.7.5 AbbVie Recent Development
11.8 Gilead Sciences
11.8.1 Gilead Sciences Company Detail
11.8.2 Gilead Sciences Business Overview
11.8.3 Gilead Sciences Influenza (Flu) Antiviral Drugs Introduction
11.8.4 Gilead Sciences Revenue in Influenza (Flu) Antiviral Drugs Business (2018-2023)
11.8.5 Gilead Sciences Recent Development
11.9 GlaxoSmithKline (GSK)
11.9.1 GlaxoSmithKline (GSK) Company Detail
11.9.2 GlaxoSmithKline (GSK) Business Overview
11.9.3 GlaxoSmithKline (GSK) Influenza (Flu) Antiviral Drugs Introduction
11.9.4 GlaxoSmithKline (GSK) Revenue in Influenza (Flu) Antiviral Drugs Business (2018-2023)
11.9.5 GlaxoSmithKline (GSK) Recent Development
11.10 Amgen
11.10.1 Amgen Company Detail
11.10.2 Amgen Business Overview
11.10.3 Amgen Influenza (Flu) Antiviral Drugs Introduction
11.10.4 Amgen Revenue in Influenza (Flu) Antiviral Drugs Business (2018-2023)
11.10.5 Amgen Recent Development
11.11 AstraZeneca
11.11.1 AstraZeneca Company Detail
11.11.2 AstraZeneca Business Overview
11.11.3 AstraZeneca Influenza (Flu) Antiviral Drugs Introduction
11.11.4 AstraZeneca Revenue in Influenza (Flu) Antiviral Drugs Business (2018-2023)
11.11.5 AstraZeneca Recent Development
11.12 Bristol-Myers Squibb
11.12.1 Bristol-Myers Squibb Company Detail
11.12.2 Bristol-Myers Squibb Business Overview
11.12.3 Bristol-Myers Squibb Influenza (Flu) Antiviral Drugs Introduction
11.12.4 Bristol-Myers Squibb Revenue in Influenza (Flu) Antiviral Drugs Business (2018-2023)
11.12.5 Bristol-Myers Squibb Recent Development
11.13 Eli Lilly
11.13.1 Eli Lilly Company Detail
11.13.2 Eli Lilly Business Overview
11.13.3 Eli Lilly Influenza (Flu) Antiviral Drugs Introduction
11.13.4 Eli Lilly Revenue in Influenza (Flu) Antiviral Drugs Business (2018-2023)
11.13.5 Eli Lilly Recent Development
11.14 Teva
11.14.1 Teva Company Detail
11.14.2 Teva Business Overview
11.14.3 Teva Influenza (Flu) Antiviral Drugs Introduction
11.14.4 Teva Revenue in Influenza (Flu) Antiviral Drugs Business (2018-2023)
11.14.5 Teva Recent Development
11.15 Bayer
11.15.1 Bayer Company Detail
11.15.2 Bayer Business Overview
11.15.3 Bayer Influenza (Flu) Antiviral Drugs Introduction
11.15.4 Bayer Revenue in Influenza (Flu) Antiviral Drugs Business (2018-2023)
11.15.5 Bayer Recent Development
11.16 Novo Nordisk
11.16.1 Novo Nordisk Company Detail
11.16.2 Novo Nordisk Business Overview
11.16.3 Novo Nordisk Influenza (Flu) Antiviral Drugs Introduction
11.16.4 Novo Nordisk Revenue in Influenza (Flu) Antiviral Drugs Business (2018-2023)
11.16.5 Novo Nordisk Recent Development
11.17 Allergan
11.17.1 Allergan Company Detail
11.17.2 Allergan Business Overview
11.17.3 Allergan Influenza (Flu) Antiviral Drugs Introduction
11.17.4 Allergan Revenue in Influenza (Flu) Antiviral Drugs Business (2018-2023)
11.17.5 Allergan Recent Development
11.18 Takeda
11.18.1 Takeda Company Detail
11.18.2 Takeda Business Overview
11.18.3 Takeda Influenza (Flu) Antiviral Drugs Introduction
11.18.4 Takeda Revenue in Influenza (Flu) Antiviral Drugs Business (2018-2023)
11.18.5 Takeda Recent Development
11.19 Boehringer Ingelheim
11.19.1 Boehringer Ingelheim Company Detail
11.19.2 Boehringer Ingelheim Business Overview
11.19.3 Boehringer Ingelheim Influenza (Flu) Antiviral Drugs Introduction
11.19.4 Boehringer Ingelheim Revenue in Influenza (Flu) Antiviral Drugs Business (2018-2023)
11.19.5 Boehringer Ingelheim Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

LIST OF TABLES & FIGURES

List of Tables
Table 1. Global Influenza (Flu) Antiviral Drugs Market Size Growth Rate by Type (US$ Million): 2018 VS 2022 VS 2029
Table 2. Key Players of Penetration and Dehulling Inhibitors
Table 3. Key Players of DNA Polymerase Inhibitors
Table 4. Key Players of Reverse Transcriptase Inhibitors
Table 5. Key Players of Protein Inhibitors
Table 6. Key Players of Neuraminidase Inhibitors
Table 7. Key Players of Broad-spectrum Antiviral Drugs
Table 8. Global Influenza (Flu) Antiviral Drugs Market Size Growth by Application (US$ Million): 2018 VS 2022 VS 2029
Table 9. Global Influenza (Flu) Antiviral Drugs Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
Table 10. Global Influenza (Flu) Antiviral Drugs Market Size by Region (2018-2023) & (US$ Million)
Table 11. Global Influenza (Flu) Antiviral Drugs Market Share by Region (2018-2023)
Table 12. Global Influenza (Flu) Antiviral Drugs Forecasted Market Size by Region (2024-2029) & (US$ Million)
Table 13. Global Influenza (Flu) Antiviral Drugs Market Share by Region (2024-2029)
Table 14. Influenza (Flu) Antiviral Drugs Market Trends
Table 15. Influenza (Flu) Antiviral Drugs Market Drivers
Table 16. Influenza (Flu) Antiviral Drugs Market Challenges
Table 17. Influenza (Flu) Antiviral Drugs Market Restraints
Table 18. Global Influenza (Flu) Antiviral Drugs Revenue by Players (2018-2023) & (US$ Million)
Table 19. Global Influenza (Flu) Antiviral Drugs Market Share by Players (2018-2023)
Table 20. Global Top Influenza (Flu) Antiviral Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Influenza (Flu) Antiviral Drugs as of 2022)
Table 21. Ranking of Global Top Influenza (Flu) Antiviral Drugs Companies by Revenue (US$ Million) in 2022
Table 22. Global 5 Largest Players Market Share by Influenza (Flu) Antiviral Drugs Revenue (CR5 and HHI) & (2018-2023)
Table 23. Key Players Headquarters and Area Served
Table 24. Key Players Influenza (Flu) Antiviral Drugs Product Solution and Service
Table 25. Date of Enter into Influenza (Flu) Antiviral Drugs Market
Table 26. Mergers & Acquisitions, Expansion Plans
Table 27. Global Influenza (Flu) Antiviral Drugs Market Size by Type (2018-2023) & (US$ Million)
Table 28. Global Influenza (Flu) Antiviral Drugs Revenue Market Share by Type (2018-2023)
Table 29. Global Influenza (Flu) Antiviral Drugs Forecasted Market Size by Type (2024-2029) & (US$ Million)
Table 30. Global Influenza (Flu) Antiviral Drugs Revenue Market Share by Type (2024-2029)
Table 31. Global Influenza (Flu) Antiviral Drugs Market Size by Application (2018-2023) & (US$ Million)
Table 32. Global Influenza (Flu) Antiviral Drugs Revenue Market Share by Application (2018-2023)
Table 33. Global Influenza (Flu) Antiviral Drugs Forecasted Market Size by Application (2024-2029) & (US$ Million)
Table 34. Global Influenza (Flu) Antiviral Drugs Revenue Market Share by Application (2024-2029)
Table 35. North America Influenza (Flu) Antiviral Drugs Market Size by Country (2018-2023) & (US$ Million)
Table 36. North America Influenza (Flu) Antiviral Drugs Market Size by Country (2024-2029) & (US$ Million)
Table 37. Europe Influenza (Flu) Antiviral Drugs Market Size by Country (2018-2023) & (US$ Million)
Table 38. Europe Influenza (Flu) Antiviral Drugs Market Size by Country (2024-2029) & (US$ Million)
Table 39. Asia-Pacific Influenza (Flu) Antiviral Drugs Market Size by Region (2018-2023) & (US$ Million)
Table 40. Asia-Pacific Influenza (Flu) Antiviral Drugs Market Size by Region (2024-2029) & (US$ Million)
Table 41. Latin America Influenza (Flu) Antiviral Drugs Market Size by Country (2018-2023) & (US$ Million)
Table 42. Latin America Influenza (Flu) Antiviral Drugs Market Size by Country (2024-2029) & (US$ Million)
Table 43. Middle East & Africa Influenza (Flu) Antiviral Drugs Market Size by Country (2018-2023) & (US$ Million)
Table 44. Middle East & Africa Influenza (Flu) Antiviral Drugs Market Size by Country (2024-2029) & (US$ Million)
Table 45. Pfizer Company Detail
Table 46. Pfizer Business Overview
Table 47. Pfizer Influenza (Flu) Antiviral Drugs Product
Table 48. Pfizer Revenue in Influenza (Flu) Antiviral Drugs Business (2018-2023) & (US$ Million)
Table 49. Pfizer Recent Development
Table 50. Roche Company Detail
Table 51. Roche Business Overview
Table 52. Roche Influenza (Flu) Antiviral Drugs Product
Table 53. Roche Revenue in Influenza (Flu) Antiviral Drugs Business (2018-2023) & (US$ Million)
Table 54. Roche Recent Development
Table 55. Sanofi Company Detail
Table 56. Sanofi Business Overview
Table 57. Sanofi Influenza (Flu) Antiviral Drugs Product
Table 58. Sanofi Revenue in Influenza (Flu) Antiviral Drugs Business (2018-2023) & (US$ Million)
Table 59. Sanofi Recent Development
Table 60. Johnson & Johnson Company Detail
Table 61. Johnson & Johnson Business Overview
Table 62. Johnson & Johnson Influenza (Flu) Antiviral Drugs Product
Table 63. Johnson & Johnson Revenue in Influenza (Flu) Antiviral Drugs Business (2018-2023) & (US$ Million)
Table 64. Johnson & Johnson Recent Development
Table 65. Merck & Co. (MSD) Company Detail
Table 66. Merck & Co. (MSD) Business Overview
Table 67. Merck & Co. (MSD) Influenza (Flu) Antiviral Drugs Product
Table 68. Merck & Co. (MSD) Revenue in Influenza (Flu) Antiviral Drugs Business (2018-2023) & (US$ Million)
Table 69. Merck & Co. (MSD) Recent Development
Table 70. Novartis Company Detail
Table 71. Novartis Business Overview
Table 72. Novartis Influenza (Flu) Antiviral Drugs Product
Table 73. Novartis Revenue in Influenza (Flu) Antiviral Drugs Business (2018-2023) & (US$ Million)
Table 74. Novartis Recent Development
Table 75. AbbVie Company Detail
Table 76. AbbVie Business Overview
Table 77. AbbVie Influenza (Flu) Antiviral Drugs Product
Table 78. AbbVie Revenue in Influenza (Flu) Antiviral Drugs Business (2018-2023) & (US$ Million)
Table 79. AbbVie Recent Development
Table 80. Gilead Sciences Company Detail
Table 81. Gilead Sciences Business Overview
Table 82. Gilead Sciences Influenza (Flu) Antiviral Drugs Product
Table 83. Gilead Sciences Revenue in Influenza (Flu) Antiviral Drugs Business (2018-2023) & (US$ Million)
Table 84. Gilead Sciences Recent Development
Table 85. GlaxoSmithKline (GSK) Company Detail
Table 86. GlaxoSmithKline (GSK) Business Overview
Table 87. GlaxoSmithKline (GSK) Influenza (Flu) Antiviral Drugs Product
Table 88. GlaxoSmithKline (GSK) Revenue in Influenza (Flu) Antiviral Drugs Business (2018-2023) & (US$ Million)
Table 89. GlaxoSmithKline (GSK) Recent Development
Table 90. Amgen Company Detail
Table 91. Amgen Business Overview
Table 92. Amgen Influenza (Flu) Antiviral Drugs Product
Table 93. Amgen Revenue in Influenza (Flu) Antiviral Drugs Business (2018-2023) & (US$ Million)
Table 94. Amgen Recent Development
Table 95. AstraZeneca Company Detail
Table 96. AstraZeneca Business Overview
Table 97. AstraZeneca Influenza (Flu) Antiviral DrugsProduct
Table 98. AstraZeneca Revenue in Influenza (Flu) Antiviral Drugs Business (2018-2023) & (US$ Million)
Table 99. AstraZeneca Recent Development
Table 100. Bristol-Myers Squibb Company Detail
Table 101. Bristol-Myers Squibb Business Overview
Table 102. Bristol-Myers Squibb Influenza (Flu) Antiviral DrugsProduct
Table 103. Bristol-Myers Squibb Revenue in Influenza (Flu) Antiviral Drugs Business (2018-2023) & (US$ Million)
Table 104. Bristol-Myers Squibb Recent Development
Table 105. Eli Lilly Company Detail
Table 106. Eli Lilly Business Overview
Table 107. Eli Lilly Influenza (Flu) Antiviral DrugsProduct
Table 108. Eli Lilly Revenue in Influenza (Flu) Antiviral Drugs Business (2018-2023) & (US$ Million)
Table 109. Eli Lilly Recent Development
Table 110. Teva Company Detail
Table 111. Teva Business Overview
Table 112. Teva Influenza (Flu) Antiviral DrugsProduct
Table 113. Teva Revenue in Influenza (Flu) Antiviral Drugs Business (2018-2023) & (US$ Million)
Table 114. Teva Recent Development
Table 115. Bayer Company Detail
Table 116. Bayer Business Overview
Table 117. Bayer Influenza (Flu) Antiviral DrugsProduct
Table 118. Bayer Revenue in Influenza (Flu) Antiviral Drugs Business (2018-2023) & (US$ Million)
Table 119. Bayer Recent Development
Table 120. Novo Nordisk Company Detail
Table 121. Novo Nordisk Business Overview
Table 122. Novo Nordisk Influenza (Flu) Antiviral DrugsProduct
Table 123. Novo Nordisk Revenue in Influenza (Flu) Antiviral Drugs Business (2018-2023) & (US$ Million)
Table 124. Novo Nordisk Recent Development
Table 125. Allergan Company Detail
Table 126. Allergan Business Overview
Table 127. Allergan Influenza (Flu) Antiviral DrugsProduct
Table 128. Allergan Revenue in Influenza (Flu) Antiviral Drugs Business (2018-2023) & (US$ Million)
Table 129. Allergan Recent Development
Table 130. Takeda Company Detail
Table 131. Takeda Business Overview
Table 132. Takeda Influenza (Flu) Antiviral DrugsProduct
Table 133. Takeda Revenue in Influenza (Flu) Antiviral Drugs Business (2018-2023) & (US$ Million)
Table 134. Takeda Recent Development
Table 135. Boehringer Ingelheim Company Detail
Table 136. Boehringer Ingelheim Business Overview
Table 137. Boehringer Ingelheim Influenza (Flu) Antiviral DrugsProduct
Table 138. Boehringer Ingelheim Revenue in Influenza (Flu) Antiviral Drugs Business (2018-2023) & (US$ Million)
Table 139. Boehringer Ingelheim Recent Development
Table 140. Research Programs/Design for This Report
Table 141. Key Data Information from Secondary Sources
Table 142. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Influenza (Flu) Antiviral Drugs Market Share by Type: 2022 VS 2029
Figure 2. Penetration and Dehulling Inhibitors Features
Figure 3. DNA Polymerase Inhibitors Features
Figure 4. Reverse Transcriptase Inhibitors Features
Figure 5. Protein Inhibitors Features
Figure 6. Neuraminidase Inhibitors Features
Figure 7. Broad-spectrum Antiviral Drugs Features
Figure 8. Global Influenza (Flu) Antiviral Drugs Market Share by Application in 2022 & 2029
Figure 9. Hospital Case Studies
Figure 10. Clinic Case Studies
Figure 11. Household Case Studies
Figure 12. Others Case Studies
Figure 13. Influenza (Flu) Antiviral Drugs Report Years Considered
Figure 14. Global Influenza (Flu) Antiviral Drugs Market Size (US$ Million), Year-over-Year: 2018-2029
Figure 15. Global Influenza (Flu) Antiviral Drugs Market Size, (US$ Million), 2018 VS 2022 VS 2029
Figure 16. Global Influenza (Flu) Antiviral Drugs Market Share by Region: 2022 VS 2029
Figure 17. Global Influenza (Flu) Antiviral Drugs Market Share by Players in 2022
Figure 18. Global Top Influenza (Flu) Antiviral Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Influenza (Flu) Antiviral Drugs as of 2022)
Figure 19. The Top 10 and 5 Players Market Share by Influenza (Flu) Antiviral Drugs Revenue in 2022
Figure 20. North America Influenza (Flu) Antiviral Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 21. North America Influenza (Flu) Antiviral Drugs Market Share by Country (2018-2029)
Figure 22. United States Influenza (Flu) Antiviral Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 23. Canada Influenza (Flu) Antiviral Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 24. Europe Influenza (Flu) Antiviral Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 25. Europe Influenza (Flu) Antiviral Drugs Market Share by Country (2018-2029)
Figure 26. Germany Influenza (Flu) Antiviral Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 27. France Influenza (Flu) Antiviral Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 28. U.K. Influenza (Flu) Antiviral Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 29. Italy Influenza (Flu) Antiviral Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 30. Russia Influenza (Flu) Antiviral Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 31. Nordic Countries Influenza (Flu) Antiviral Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 32. Asia-Pacific Influenza (Flu) Antiviral Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 33. Asia-Pacific Influenza (Flu) Antiviral Drugs Market Share by Region (2018-2029)
Figure 34. China Influenza (Flu) Antiviral Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 35. Japan Influenza (Flu) Antiviral Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 36. South Korea Influenza (Flu) Antiviral Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 37. Southeast Asia Influenza (Flu) Antiviral Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 38. India Influenza (Flu) Antiviral Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 39. Australia Influenza (Flu) Antiviral Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 40. Latin America Influenza (Flu) Antiviral Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 41. Latin America Influenza (Flu) Antiviral Drugs Market Share by Country (2018-2029)
Figure 42. Mexico Influenza (Flu) Antiviral Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 43. Brazil Influenza (Flu) Antiviral Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 44. Middle East & Africa Influenza (Flu) Antiviral Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 45. Middle East & Africa Influenza (Flu) Antiviral Drugs Market Share by Country (2018-2029)
Figure 46. Turkey Influenza (Flu) Antiviral Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 47. Saudi Arabia Influenza (Flu) Antiviral Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 48. Pfizer Revenue Growth Rate in Influenza (Flu) Antiviral Drugs Business (2018-2023)
Figure 49. Roche Revenue Growth Rate in Influenza (Flu) Antiviral Drugs Business (2018-2023)
Figure 50. Sanofi Revenue Growth Rate in Influenza (Flu) Antiviral Drugs Business (2018-2023)
Figure 51. Johnson & Johnson Revenue Growth Rate in Influenza (Flu) Antiviral Drugs Business (2018-2023)
Figure 52. Merck & Co. (MSD) Revenue Growth Rate in Influenza (Flu) Antiviral Drugs Business (2018-2023)
Figure 53. Novartis Revenue Growth Rate in Influenza (Flu) Antiviral Drugs Business (2018-2023)
Figure 54. AbbVie Revenue Growth Rate in Influenza (Flu) Antiviral Drugs Business (2018-2023)
Figure 55. Gilead Sciences Revenue Growth Rate in Influenza (Flu) Antiviral Drugs Business (2018-2023)
Figure 56. GlaxoSmithKline (GSK) Revenue Growth Rate in Influenza (Flu) Antiviral Drugs Business (2018-2023)
Figure 57. Amgen Revenue Growth Rate in Influenza (Flu) Antiviral Drugs Business (2018-2023)
Figure 58. AstraZeneca Revenue Growth Rate in Influenza (Flu) Antiviral Drugs Business (2018-2023)
Figure 59. Bristol-Myers Squibb Revenue Growth Rate in Influenza (Flu) Antiviral Drugs Business (2018-2023)
Figure 60. Eli Lilly Revenue Growth Rate in Influenza (Flu) Antiviral Drugs Business (2018-2023)
Figure 61. Teva Revenue Growth Rate in Influenza (Flu) Antiviral Drugs Business (2018-2023)
Figure 62. Bayer Revenue Growth Rate in Influenza (Flu) Antiviral Drugs Business (2018-2023)
Figure 63. Novo Nordisk Revenue Growth Rate in Influenza (Flu) Antiviral Drugs Business (2018-2023)
Figure 64. Allergan Revenue Growth Rate in Influenza (Flu) Antiviral Drugs Business (2018-2023)
Figure 65. Takeda Revenue Growth Rate in Influenza (Flu) Antiviral Drugs Business (2018-2023)
Figure 66. Boehringer Ingelheim Revenue Growth Rate in Influenza (Flu) Antiviral Drugs Business (2018-2023)
Figure 67. Bottom-up and Top-down Approaches for This Report
Figure 68. Data Triangulation
Figure 69. Key Executives Interviewed

Offer REPORT BUYING OPTIONS

USD GBP EURO YEN Single User Price
USD GBP EURO YEN Multi User Price
USD GBP EURO YEN Enterprise Price

---- OR ----

Frequently Asked Questions ?

  • Upto 24 hrs - Working days
  • Upto 48 hrs max - Weekends and public holidays
  • Single User License
    A license granted to one user. Rules or conditions might be applied for e.g. the use of electric files (PDFs) or printings, depending on product.

  • Multi user License
    A license granted to multiple users.

  • Site License
    A license granted to a single business site/establishment.

  • Corporate License, Global License
    A license granted to all employees within organisation access to the product.
  • Online Payments with PayPal and CCavenue
  • Wire Transfer/Bank Transfer
  • Email
  • Hard Copy

Our Key Features

  • Data Accuracy and Reliability
  • Data Security
  • Customized Research
  • Trustworthy
  • Competitive Offerings
check discount